Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
GAITHERSBURG, Md., Sept. 07, 2016 -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived audio of the presentation will also be available on OpGen’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contacts:
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
[email protected]
[email protected]
Investor Relations
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]
Bruce Voss
(310) 691-7100
[email protected]
OpGen Media
MacDougall Biomedical Communications
Cammy Duong
(781) 235-3060
[email protected]
